Skip to content

Illumina Partnerships

Collaborating to Advance Genomics

As a global leader in genomics, we continually strive to offer solutions that are not only innovative, but also accessible and always reliable. Illumina partnerships help advance genomics in numerous ways, from expanding access to next-generation sequencing (NGS) to pioneering new applications, providing funding for innovative startups, and more. 

Collaborative Partnerships

Sequencing Service Provider Program

The Illumina Propel Certification Program provides your lab with the opportunity to demonstrate competency with select Illumina products through a carefully designed, standardized process. Propel Certification also offers a number of powerful benefits such as preferred pricing on selected products and services and the ability to list your service lab on Illumina.com.

Learn More
Accelerator Startup Funding
Startup Funding for Genomics Companies

With mentorship, financial support, and access to sequencers and reagents, the Illumina Accelerator is helping genomics startups launch so we can unlock the power of the genome—together.

Illumina Accelerator Startup Funding

Featured Pharmaceutical & Biotech Partnerships

Some of our existing partnerships include:

Roche

Illumina and Roche partner to broaden the adoption of distributable next-generation sequencing-based testing in oncology.

Read Press Release
Bristol-Myers Squibb

Bristol-Myers Squibb and Illumina collaborate to commercialize companion diagnostics for oncology immunotherapies.

Read Press Release
Loxo Oncology

Illumina and Loxo Oncology partner to develop next-generation sequencing-based pan-cancer companion diagnostics.

Read Press Release

Illumina Press Releases

Discover additional partnerships and stay informed about breaking Illumina news.

Featured Press Releases
Illumina and QIAGEN Partner on Sequencing-Based In-Vitro Diagnostic (IVD) Tests

The partnership will initially focus on commercializing oncology IVD kits to support patient management and may expand in the future to include additional clinical diagnostic fields.

Illumina and the Broad Institute Partner to Co-develop Secondary Analysis Tools

The partnership will result in new methods, integrating Illumina DRAGEN Pipelines and technology with the Broad’s Genome Analysis Toolkit (GATK).